Therapeutic interventions that stop or reverse age-related damage throughout the whole body system.
Towards the end of last year, we unveiled the Ten Levels of Longevity framework, a structured and detailed guide designed to navigate the expanding field of longevity science. Following our discussion of Level 7, which explored targeted aging disease reversal, we now move to Level 8: systemic aging reversal.
Level 8: Systemic aging reversal
Therapeutic interventions that stop or reverse age-related damage throughout the whole body system.
Systemic aging reversal encompasses therapeutic interventions aimed at halting or reversing age-related damage across the entire body. Unlike targeted approaches that focus on specific tissues or organs, this level seeks to rejuvenate the body’s systems holistically, addressing the fundamental mechanisms of aging at a cellular and molecular level. Techniques such as partial cellular reprogramming and the elimination of senescent cells are central to this strategy, aiming to restore youthful function and resilience throughout the organism.
Investment opportunities in systemic aging reversal
The field of systemic aging reversal is in its nascent stages, attracting interest primarily from ultra-high-net-worth individuals and specialized venture capitalists. Investment opportunities are emerging in areas such as partial cellular reprogramming, which endeavors to reset cellular age without compromising cell identity and senotherapeutics targeting the removal of senescent cells to promote regeneration. Additionally, companies addressing mitochondrial dysfunction to rejuvenate cellular energy production present promising prospects. Investors with a long-term vision and an appetite for pioneering science may find substantial potential in this evolving sector.
Companies active at Level 8
Mitrix Bio
Mitrix Bio is pioneering an innovative approach to reversing age-related mitochondrial dysfunction. The company grows young mitochondria in bioreactors and encapsulates them in vesicles called “Mitlets,” which can be absorbed by cells to replace damaged mitochondria. This technique aims to rejuvenate cellular function, boost energy production and slow down aging. Mitrix Bio’s work extends across multiple longevity levels, including Level 7 (targeted aging disease reversal) and Level 6 (aging disease prevention therapeutics).
Turn Biotechnologies
Turn Biotechnologies focuses on mRNA-based epigenetic reprogramming therapies to restore optimal gene expression and counteract age-related epigenomic changes. Their Epigenetic Reprogramming of Aging (ERA) technology seeks to reverse cellular aging at a molecular level. The company’s therapeutic pipeline includes applications for dermatology, ophthalmology and immunology, positioning it at the forefront of systemic aging reversal while also contributing to targeted aging disease reversal (Level 7).
Rubedo Life Sciences
Rubedo Life Sciences develops senotherapeutic drugs designed to selectively eliminate senescent cells, which drive inflammation and tissue degeneration. By removing these cells, their treatments aim to slow age-related diseases such as dermatitis and psoriasis, promoting systemic rejuvenation. Their work overlaps with Level 7 (targeted aging disease reversal) and Level 6 (aging disease prevention therapeutics).
Sentaur Biosciences
Sentaur Biosciences specializes in antibody-based therapies to remove senescent cells. Their focus includes conditions like pulmonary fibrosis, kidney disease and osteoarthritis—diseases closely linked to aging. By eliminating these harmful cells, Sentaur’s approach aligns with systemic aging reversal and could significantly improve longevity outcomes.
Zoe Biosciences
Zoe Biosciences targets the PAI-1/apelin axis, a key biological pathway implicated in aging and metabolic disorders. The company is developing PAI-1 inhibitors to address the underlying causes of age-related metabolic dysfunction, aiming to extend healthspan and mitigate chronic disease risks. Their work also extends into targeted disease reversal (Level 7).
Cellaax
Cellaax is advancing cell-based therapies designed to regenerate damaged tissues. Using approaches that include mesenchymal stem cells, immunotherapy and secretome therapy, their research focuses on age-related respiratory diseases, including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). By targeting cellular aging on a systemic scale, Cellaax is contributing to breakthroughs in both Level 8 systemic aging reversal and Level 7 targeted interventions.
StarkAge
StarkAge, a French biotechnology company, is developing immunotherapies to selectively eliminate senescent cells. By addressing cellular senescence, their treatments aim to delay the onset of age-related diseases and extend healthy lifespan. Their focus aligns with systemic aging reversal while also contributing to disease prevention (Level 6) and targeted reversal (Level 7).
These companies represent the developing field of systemic aging reversal, and they are working to develop breakthrough therapies that could redefine human longevity.
Check out our look at Levels 1 (lifestyle management), 2 (consumer diagnostics), 3 (longevity supplements), 4 (longevity clinics), 5 (aging disease management), 6 (aging disease prevention therapeutics) and 7 (targeted aging disease reversal) HERE and stay tuned for Levels 9 and 10 coming over the next few weeks!
